TGFB1 and glioblastoma: Hence, our analysis suggests that a combined therapy targeting RAS and TGFB1 or their downstream targets could have a synergistic therapeutic effect for glioblastoma, again demonstrating the potential of SiPSiC analysis to accelerate the development of targeted therapy.